Objective: Galantamine is a new nootropic agent a dual mechanism of action on the cholinergic system. It leads to increase the nicotinic neurotransmission of the acetylcholine, thus controlling the release of the different intervening neurotransmitters wich modulate the mechanisms of the memory and the learning. The efficacy, safety and tolerability of galantamine were assessed taking into account profile of patients with Mild Neurocognitive Disorder from the clinical aspects and the different classifications.
Design: Multicenter and open-label study, prospective and observational trial in 258 out-patients.
Materials and Methods: The experience included 258 out-patients with Mild Neurocognitive Disorder, who receive either 8 mg/day or 16 mg/day of galantamine for a 12 month treatment.
Results: The therapeutic response was measured using the Mini Mental State Exmination and the Clinical Global Impression Scale, taking into account the efficacy, safety an adverse events of the treatment.
Conclusion: The final results of the study showed that galantamine improves cognition, behavioral symptoms and the general state well-being of patients with mild cognitive impairment. The best therapeutic response was observed in the group wich received 16 mg/day; the incidence of adverse events was not significant and a very good profile of tolerability and safety was observed.
Back to PB Tuesday Poster Sessions
Back to The Eleventh International Congress